s and inhibits the signaling of IL-31, will explore its efficacy and safety in different patient populations with moderate-to-severe atopic dermatitis.1-4,15-17 This includes a late-breaking presentation assessing the pharmacokinetics, safety and efficacy of nemolizumab in pediatric patients (aged 2 to 11 years) on Saturday, March 28 at 10:24-10:36 AM MDT / 5:24-5:36 PM CET in Bellco Theatre 3.1 Additionally, an oral presentation of post hoc data from the ARCADIA long-term extension trial, taking place on Saturday, March 28 at 2:10-2:15 PM MDT / 9:10-9:15 PM CET in Lobby C, Poster Center 2, will look at the long-term maintenance of itch and skin responses with Nemluvio up to 104 weeks.2 Two other posters will display data on Nemluvio’s long-term efficacy and safety up to two years in adolescents, and in patients with partial and minimal skin response at 16 weeks.3,4

Our product theater on Sunday, March 29 at 10:30-11:15 AM MDT / 6:30-7:15 PM CET in Theatre 1 will delve into t
=*=*=*=*=*=
当前为第4/17页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页